The insider selling is routine and non-informative given the small size relative to market cap and the simultaneous equity grants. Monitor for any upcoming catalyst (e.g., clinical data readout) that could explain the timing, but this cluster alone does not warrant a bearish stance. The strong historical performance of prior bullish calls on ARTV suggests the stock may continue to trend higher on its own merits.
Price Chart
Executive Summary
A cluster of insider selling at Artiva Biotherapeutics, totaling $477K, was driven by the CEO, COO, CTO, and CMO. The CEO's $256K sale is the largest, but the total represents only ~0.09% of the $509M market cap, falling below the 0.1% materiality threshold. This is a routine, low-significance event, especially given the simultaneous large equity grants to the same executives, which are non-cash and likely set up a 10b5-1 plan for tax or diversification purposes. The historical performance on this ticker is strong, but this specific event lacks the conviction of prior cluster buys that drove significant alpha.
Key Financial Metrics
Key Facts
- Total insider selling of $477K represents ~0.09% of ARTV's $509M market cap, below the 0.1% materiality threshold.
- CEO Fred Aslan sold 23,429 shares for $256K on 2026-09-08, the largest single trade in the cluster.
- COO Jennifer Bush, CTO Christopher Horan, and CMO Subhashis Banerjee also sold shares totaling $222K on 2026-09-03.
- All four selling insiders received large equity grants on 2026-09-09 (non-cash, $0 value), suggesting the sales may be liquidity-driven to cover taxes or diversify after vesting.
- No open-market buying was reported in the cluster, and all sales are open-market (code S).
Financial Impact
Total insider sales of $477K, or ~0.09% of market cap. No material financial impact.
Risk Factors
- Insider selling could accelerate if the stock price rises further, creating overhead supply.
- The company is a pre-revenue biotech with no approved products, so any clinical or regulatory setback could be severe.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-ARTV-1789168934207 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 20d ago | 8-K | $10.14 $8.91 | ▼ −12.13% | ▼ −11.67% | $6.86 (−32.35%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▼ −3.43% | ▼ −2.83% | $6.86 (−36.42%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▼ −3.43% | ▼ −2.83% | $6.86 (−36.42%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▼ −3.43% | ▼ −2.83% | $6.86 (−36.42%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▼ −3.43% | ▼ −2.83% | $6.86 (−36.42%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▲ +3.43% | ▲ +2.83% | $6.86 (+36.42%) |
Sep 4, 2026 28d ago | Insider Cluster | $11.19 $10.88 | ▼ −2.77% | ▼ −2.22% | $6.86 (−38.70%) |
Aug 15, 2026 6w ago | Institutional Cluster | $11.74 $11.68 | ▼ −0.51% | ▲ +0.16% | $6.86 (−41.57%) |
Jul 31, 2026 8w ago | Insider Buy | $10.76 $11.07 | ▲ +2.88% | ▲ +1.08% | $6.86 (−36.25%) |
Jul 28, 2026 9w ago | Insider Buy | $10.53 $10.02 | ▼ −4.84% | ▼ −3.30% | $6.86 (−34.85%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access